Program Chair Kelly Nichols, OD, MPH, PhD, FAAO, along with panelists Francis S. Mah, MD, and Walter O. Whitley, OD, MBA, FAAO, have a lively and informative discussion on neurotrophic keratitis.
This chapter includes the following topics: NK Treatments; The Latest Treatment Options; and Cenegermin-bkbj Clinical Data.
This activity is supported by unrestricted educational grant from Dompé.
Upon completion of this activity, the participant should be able to:
Sponsored by 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 124432, is accredited by COPE for continuing education for optometrists. This course is approved for 0.5 hours of CE.
Course ID # 79365-TD
Activity ID # 124432
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Kelly K. Nichols, OD, MPH, PhD, FAAO
Professor and Dean
University of Alabama at Birmingham
School of Optometry
Birmingham, AL
Francis Mah, MD
Director of Corneal and External Disease
Co-Director of Refractive Surgery
Scripps Clinic
La Jolla, CA
Walter O. Whitley, OD, MBA, FAAO
Director of Optometric Services
Virginia Eye Consultants
Norfolk, VA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alderya, Allergan/AbbVie, Axim, Bausch + Lomb, Bruder Healthcare, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica/RVL, Oyster Point Pharma, Palatin, Sight Sciences, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, Tear Film Innovations/Alcon, TearSolutions, Thea, TopiVert, Versea Visionology, Xequel, and YuYu Pharma. Grant/Research: Allergan/AbbVie, Aramis, Kala Pharmaceuticals, Kowa, ScienceBased Health, Sylentis, and Tear Science. Stock/Shareholder: Visionology.
Francis Mah, MD, has had a financial agreement or affiliation during the past year with the following ineligible companies in the form of Consultant: Alcon, Allergan/AbbVie, Dompé, Johnson & Johnson Vision, Kiova, Novartis, Santen, and Sun Pharmaceutical Industries. Speaker’s Bureau: Dompé, Johnson & Johnson Vision, Santen, Sun Pharmaceutical Industries, and Tarsus Pharmaceuticals.
Walter O. Whitley, OD, MBA, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Bausch + Lomb, Bio-Tissue, Bruder Healthcare, Eyevance, Glaukos, Horizon Therapeutics, Johnson & Johnson Vision, Kala Pharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Ocusoft, Oyster Point Pharma, Quidel, Regener-Eyes, RVL Pharmaceuticals, ScienceBased Health, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, TearLab, and Thea Pharmaceuticals. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Bausch + Lomb, Bio-Tissue, Eyevance, Novartis, ScienceBased Health, and Sun Pharmaceutical Industries. Share/Stockholder: Leo Lens Technology.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Dompé.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
1.00 program credit
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
